![](https://sparc.life/wp-content/uploads/2023/09/biomodifying.png)
Biomodifying
In-licensed anti MUC-1 antibodies targeting several cancers
![](https://sparc.life/wp-content/uploads/2023/09/bioprojet-1.png)
Bioproject
In-licensed Vibozilimod for treatment of auto-immune disorders
![](https://sparc.life/wp-content/uploads/2023/09/instem.png)
InStem
To identify inhibitors of a novel target to address PARP resistance in solid tumours
![](https://sparc.life/wp-content/uploads/2023/09/michigan-university.png)
University Of Michigan
To evaluate anti-MUC-1 ADC in preclinical models
![](https://sparc.life/wp-content/uploads/2023/09/sripps-research.png)
Scripps Research
To investigate the effect of SPARC NCEs on modulating autophagy and inflammasome
![](https://sparc.life/wp-content/uploads/2023/09/sun-pharma.png)
Sun Pharma
Out-licensed Xelpros, Vibozilimod and Sezaby
![](https://sparc.life/wp-content/uploads/2023/09/tripoint.png)
Tripoint Therapeutics
Out-licensed Elepsia 1000mg and 1500mg
![](https://sparc.life/wp-content/uploads/2023/09/uk-dementia.png)
UK Dementia Research Institute
To identify targets and potential modulators of proteotoxicity in Alzheimer’s Disease
![](https://sparc.life/wp-content/uploads/2023/09/visiox.png)
Visiox
Out-licensed Brimonidine and Difluprednate
![](https://sparc.life/wp-content/uploads/2023/09/washington-university.png)
Washington University
To study Abl kinase inhibitors in models of neurodegeneration